NCT00001575View on ClinicalTrials.gov

Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

April 30, 1997

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Hodgkin's DiseaseLymphoma, Non-Hodgkin
Interventions
BIOLOGICAL

Y-90 Humanized Anti-Tac

10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).

DRUG

Calcium-DTPA

Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH